TY - JOUR
T1 - Total and free vitamin D metabolites in patients with primary hyperparathyroidism
AU - Meng, L.
AU - Su, C.
AU - Shapses, S. A.
AU - Wang, X.
N1 - Funding Information:
This work was partially supported by the National Institute of Aging (NIH-AG12161) and a NIFA-USDA (NJAES-0153866) (S.A.S). The funders played no role in the study design, data collection and interpretation of data, writing of the article, or the decision to submit the manuscript for publication.
Publisher Copyright:
© 2021, Italian Society of Endocrinology (SIE).
PY - 2022/2
Y1 - 2022/2
N2 - Purpose: To evaluate total and free vitamin D metabolites and hormone-to-prohormone [1,25(OH)2D/25(OH)D] “activation ratio” in PHPT patients with low or insufficient vitamin D status. Methods: Thirty female patients with primary hyperparathyroidism (PHPT) and 30 age and body mass index (BMI) matched healthy controls were enrolled. Serum levels of calcium, intact parathyroid hormone (iPTH), vitamin D binding protein (DBP), albumin, total 25(OH)D and 1,25(OH)2D were measured. The activation ratio of vitamin D was calculated as total 1,25(OH)2D/25(OH)D. Calculated serum-free 25(OH)D and 1,25(OH)2D levels were also reported. Results: Compared to the control subject, patients with PHPT had a lower total 25(OH)D and DBP levels (p < 0.001). The serum concentration of free 25(OH)D and total 1,25(OH)2D were similar between the two groups; but free 1,25(OH)2D levels were about 26% higher in the PHPT patients compared to controls (p < 0.001). PHPT patients had a significantly higher activation ratio (p < 0.01), although their total 25(OH)D were lower than controls. The free (but not total) 1,25(OH)2D level was inversely correlated with DBP (p < 0.01). Both free 1,25(OH)2D levels and activation ratio were positively correlated with iPTH and calcium levels (p < 0.01). The activation ratio was highly correlated with levels of total vitamin D stores and free vitamin D metabolites (p < 0.001). Conclusion: Patients with PHPT had significantly higher free 1,25(OH)2D levels and activation ratio compared to control subjects. We suggest that levels of free vitamin D metabolites and vitamin D activation ratio may provide additional values for the diagnosis and therapeutic choices in these patient populations with compromised vitamin D status.
AB - Purpose: To evaluate total and free vitamin D metabolites and hormone-to-prohormone [1,25(OH)2D/25(OH)D] “activation ratio” in PHPT patients with low or insufficient vitamin D status. Methods: Thirty female patients with primary hyperparathyroidism (PHPT) and 30 age and body mass index (BMI) matched healthy controls were enrolled. Serum levels of calcium, intact parathyroid hormone (iPTH), vitamin D binding protein (DBP), albumin, total 25(OH)D and 1,25(OH)2D were measured. The activation ratio of vitamin D was calculated as total 1,25(OH)2D/25(OH)D. Calculated serum-free 25(OH)D and 1,25(OH)2D levels were also reported. Results: Compared to the control subject, patients with PHPT had a lower total 25(OH)D and DBP levels (p < 0.001). The serum concentration of free 25(OH)D and total 1,25(OH)2D were similar between the two groups; but free 1,25(OH)2D levels were about 26% higher in the PHPT patients compared to controls (p < 0.001). PHPT patients had a significantly higher activation ratio (p < 0.01), although their total 25(OH)D were lower than controls. The free (but not total) 1,25(OH)2D level was inversely correlated with DBP (p < 0.01). Both free 1,25(OH)2D levels and activation ratio were positively correlated with iPTH and calcium levels (p < 0.01). The activation ratio was highly correlated with levels of total vitamin D stores and free vitamin D metabolites (p < 0.001). Conclusion: Patients with PHPT had significantly higher free 1,25(OH)2D levels and activation ratio compared to control subjects. We suggest that levels of free vitamin D metabolites and vitamin D activation ratio may provide additional values for the diagnosis and therapeutic choices in these patient populations with compromised vitamin D status.
KW - 1,25-Dihydroxyvitamin D
KW - Hyperparathyroidism
KW - Parathyroid hormone
KW - Vitamin D
KW - Vitamin D activation ratio
UR - http://www.scopus.com/inward/record.url?scp=85110852435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110852435&partnerID=8YFLogxK
U2 - 10.1007/s40618-021-01633-1
DO - 10.1007/s40618-021-01633-1
M3 - Article
C2 - 34282553
AN - SCOPUS:85110852435
SN - 0391-4097
VL - 45
SP - 301
EP - 307
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
IS - 2
ER -